WDNA - ETF AI Analysis
Top Page
WisdomTree BioRevolution Fund (WDNA)
WDNA, the WisdomTree BioRevolution Fund, appears to be a solid but not top-tier option, with its rating driven by a mix of strong blue-chip and innovative biotech holdings alongside more financially challenged names. High-quality companies like Johnson & Johnson, Eli Lilly, United Therapeutics, and Natera support the fund’s quality through strong financial performance, revenue growth, and generally positive momentum, while weaker holdings such as Twist Bioscience and Iovance Biotherapeutics, which face ongoing losses and bearish or mixed technical trends, weigh on the overall rating. The main risk factor is the fund’s concentration in biotech and life sciences, where many companies have profitability and valuation challenges, making the ETF more sensitive to sector-specific setbacks and volatility.
WDNA vs. SPDR S&P 500 ETF (SPY)
- AUM
- 5.02M
- Region
- Developed Markets
- Expense Ratio
- 0.45%
- Beta
- 0.92
- Issuer
- WisdomTree
- Inception Date
- Jun 03, 2021
- Dividend Yield
- 3.13%
- Asset Class
- Equity
- Index Tracked
- WisdomTree BioRevolution Index
WDNA Summary
WDNA is an ETF that follows the WisdomTree BioRevolution Index, focusing on companies using genetics and biotechnology to change healthcare, agriculture, and other industries. It holds firms involved in gene editing, personalized medicine, and advanced lab tools, including well-known names like Eli Lilly and Moderna. Someone might invest in WDNA for growth potential and to get diversified exposure to many innovative biotech companies in a single fund. However, it is heavily focused on health care and biotech, so its price can be very volatile and may go up and down sharply with changes in the sector.
How much will it cost me?
This ETF has an expense ratio of 0.45%, which means you’ll pay about $4.50 per year for every $1,000 invested. That’s higher than the average low-cost index ETF because it’s a specialized, actively managed fund focused on cutting-edge genomics and biotechnology companies.
What would affect this ETF?
This ETF could benefit if breakthroughs in genomics and biotechnology lead to new successful drugs, wider use of personalized medicine, and supportive healthcare regulations in developed markets, helping companies like Eli Lilly, Moderna, and other top holdings grow. On the downside, it is heavily concentrated in health care, so setbacks like failed clinical trials, tighter drug pricing rules, or reduced funding for biotech research could hurt many of its holdings at the same time.
WDNA Top 10 Holdings
WDNA is essentially a bet on the BioRevolution, with heavyweight positions in Moderna and Twist Bioscience setting the tone. Both have been rising lately, giving the fund a strong push from the cutting edge of vaccines and synthetic DNA. 10x Genomics and Natera add more momentum in genomic tools and testing, while Tempus AI brings a data-driven twist to precision medicine. Blue-chip anchors like Eli Lilly and Johnson & Johnson are steadier, helping balance out more volatile names. The portfolio is heavily tilted toward U.S. healthcare and biotech, with little exposure beyond developed markets.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 TWST | Twist Bioscience | 4.04% | $208.49K | $11.42B | 416.68% | 43Neutral |
 LLY | Eli Lilly & Co | 3.24% | $167.48K | $1.21T | 57.09% | 72Outperform |
 TEM | Tempus AI, Inc. Class A | 3.53% | $182.41K | $13.96B | -11.53% | 52Neutral |
 NTRA | Natera | 3.05% | $157.46K | $61.18B | 123.89% | 73Outperform |
 IMNM | Immunome | 2.75% | $141.84K | $2.21B | 14.46% | 63Neutral |
 MRNA | Moderna | 2.67% | $138.14K | $85.50B | 744.83% | 59Neutral |
 TMO | Thermo Fisher | 2.44% | $126.04K | $260.36B | 26.28% | 72Outperform |
 TXG | 10x Genomics | 2.53% | $130.87K | $10.89B | 526.84% | 60Neutral |
 UTHR | United Therapeutics | 2.09% | $107.91K | $25.15B | 41.20% | 79Outperform |
 STOK | Stoke Therapeutics | 2.17% | $111.95K | $1.70B | -16.50% | 70Outperform |
WDNA Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For WDNA, the sentiment is Positive. The current price of 24.61 is above the 20-day moving average (MA) of 23.25, above the 50-day MA of 23.28, and above the 200-day MA of 19.72, indicating a bullish trend. The MACD of 0.18 indicates Negative momentum. The RSI at 62.23 is Neutral, neither overbought nor oversold. The STOCH value of 87.09 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for WDNA.
WDNA Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| WDNA | $24.61 | $23.00(-6.52% Downside) | $5.02M | 0.45% | 58Neutral |
 AGNG | $38.56 | $43.32(12.35% Upside) | $93.25M | 0.50% | 64Neutral |
 WISE | $33.48 | $69.39(107.26% Upside) | $23.49M | 0.35% | 57Neutral |
 FOWF | $35.04 | $46.07(31.50% Upside) | $14.85M | 0.49% | 70Neutral |
 IVEP | $24.37 | $34.47(41.46% Upside) | $14.44M | 0.75% | 70Outperform |
 SPAM | $49.58 | $54.55(10.03% Upside) | $7.51M | 0.35% | 64Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| WDNA | WisdomTree BioRevolution Fund | 24.61 | 8.40 | 51.87% | |
| AGNG | Global X Aging Population ETF | 38.56 | 4.97 | 14.79% | |
| WISE | Themes Generative Artificial Intelligence ETF | 33.48 | -10.11 | -23.20% | |
| FOWF | Pacer Solactive Whitney Future of Warfare ETF | 35.04 | 3.88 | 12.45% | |
| IVEP | Dan IVES Wedbush AI Power & Infrastructure ETF | 24.37 | -1.73 | -6.63% | |
| SPAM | Themes Cybersecurity ETF | 49.58 | 15.27 | 44.51% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.